Pharmacovigilance in patients with diabetes: A data-driven analysis identifying specific RAS antagonists with adverse pulmonary safety profiles that have implications for COVID-19 morbidity and mortality

OBJECTIVES: The current demographic information from China reports that 10%-19% of patients hospitalized with coronavirus disease (COVID-19) were diabetic. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are considered first-line agents in patients with d...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Am Pharm Assoc (2003)
Autores principales: Stafford, Emma G., Riviere, Jim E., Xu, Xuan, Kawakami, Jessica, Wyckoff, Gerald J., Jaberi-Douraki, Majid
Formato: Artigo
Lenguaje:Inglês
Publicado: American Pharmacists Association®. Published by Elsevier Inc. 2020
Materias:
Science and Practice
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7262497/
https://ncbi.nlm.nih.gov/pubmed/32561317
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.japh.2020.05.018
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares